Drug-Coated Balloons for Heart Attacks Caused by Plaque Erosion
Compares drug-coated balloon treatment with medicines in adults having a heart attack from plaque erosion.
Plain-language title generated from the registry record
Registry title: Investigation to Assess the Effects of Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes
Key facts
- Where
- Lubin, PolandSee the site
Where in Poland
- Miedziowe Centrum Zdrowia SALubin, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- 3W-Research Collaboration Group
- Trial code
- NCT07783880
- Record updated
- 25 August 2026
- Original description
Drug eluting balloon angioplasty might be a better alternative than medical treatment or stenting in subjects with plaque erosion, which is the second most common cause of myocardial infarction.Read full original descriptionShow less
Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes
Drug eluting balloon angioplasty might be a better alternative than medical treatment or stenting in subjects with plaque erosion, which is the second most common cause of myocardial infarction.
The main objective of this pilot study is to gain clear insights on the effect of percutaneous coronary intervention (PCI) with size matched DCB (SeQuent) as compared to treatment with GP IIbIIIa inhibitor or heparin \& dual antiplatelet therapy in a predominantly Caucasian population at 2 days and at 1 year after the procedure.
Inclusion: Patients aged ≥18 years presenting with MI where the culprit de-novo (stent restenosis/thrombosis excluded) lesion has a Thrombolysis in Myocardial Infarction (TIMI) flow of ≥ I with signs of thrombus on angiographic (or CCTA followed by conventional coronary angiography) evaluation located in a native coronary artery (a by-pass graft vessel excluded) addressable by PCI; OCT criteria (all 4 should be present):; Presence of thrombus; Absence of an overt ruptured plaque flap; Area of stenosis of ≥ 50%; Presence of atherosclerotic, predominantly lipidic or fibrotic plaque underneath (absence of major calcifications or calcified noduli).
Exclusion: Renal insufficiency (Glomerular Filtration Rate (GFR) < 29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5); Predominantly calcific lesions with calcium arc > 180° in the target segment; Presence of calcium plaque of > 0.4 mm thick; Culprit lesion located or extending in the Left Main coronary artery; Presence of large coronary aneurysms; Large thrombus burden (extending for more than > 15 mm); Patients with severe tortuous lesions (OCT judged not possible); Spontaneous coronary dissection is suspected; Life expectancy less than 2 years; Pregnant or lactating women; Patients currently participating in another trial; Patients that are unable or unwilling to provide consent; OCT exclusion criteria:; Overt plaque rupture; Thrombosed protruding calcified noduli.